| 1. |
- Samnegård, Ulrika, et al.
(författare)
-
Within-bloom shift in abundance of a wild pollinator mediates pollen deposition rates to blueberry
- 2023
-
Ingår i: Basic and Applied Ecology. - 1439-1791. ; 72, s. 64-73
-
Tidskriftsartikel (refereegranskat)abstract
- Intra-seasonal variation in abiotic and biotic conditions can have profound consequences for pollinator community compositions and foraging movement, with flow-on effects upon pollination services. Yet, few studies have related such variations to pollination services in crop systems. In a cultivated highbush blueberry system with two primary pollinators — the managed European honey bee and a wild stingless bee species — we investigated how pollinator abundances, bee foraging behaviour, and con- and heterospecific stigmatic pollen loads changed over early, mid, and late blueberry blooming. Both con- and heterospecific stigmatic pollen loads declined following early bloom. This shift was associated with a decline in the abundance of stingless bees, whereas the abundance of honey bees only declined during late bloom. Simultaneously, honey bees were more likely to forage for blueberry pollen, and stigmatic pollen loads, relative to bee abundance, increased during late bloom. Although mixed pollen loads were common on pollinator bodies, especially on pollen foraging honey bees, heterospecific pollen deposition on blueberry stigmas was low. Given the similar effectiveness of honey bees and stingless bees as pollinators of blueberries, we contend that the observed seasonal variation in pollen deposition is likely caused by the decline in stingless bee abundances, as honey bees were not able to fully compensate for the loss of stingless bees during late bloom. Greater consideration of seasonal heterogeneity of pollinator abundance and behaviour, as part of pollination management plans, may aid in ensuring high pollination services throughout the entirety of crop bloom.
|
|
| 2. |
- Steimer, Jean-Louis, et al.
(författare)
-
Modelling the genesis and treatment of cancer : the potential role of physiologically based pharmacodynamics
- 2010
-
Ingår i: European Journal of Cancer. - : Elsevier BV. - 0959-8049 .- 1879-0852. ; 46:1, s. 21-32
-
Tidskriftsartikel (refereegranskat)abstract
- Physiologically based modelling of pharmacodynamics/toxicodynamics requires an a priori knowledge on the underlying mechanisms causing toxicity or causing the disease. In the context of cancer, the objective of the expert meeting was to discuss the molecular understanding of the disease, modelling approaches used so far to describe the process, preclinical models of cancer treatment and to evaluate modelling approaches developed based on improved knowledge. Molecular events in cancerogenesis can be detected using 'omics' technology, a tool applied in experimental carcinogenesis, but also for diagnostics and prognosis. The molecular understanding forms the basis for new drugs, for example targeting protein kinases specifically expressed in cancer. At present, empirical preclinical models of tumour growth are in great use as the development of physiological models is cost and resource intensive. Although a major challenge in PKPD modelling in oncology patients is the complexity of the system, based in part on preclinical models, successful models have been constructed describing the mechanism of action and providing a tool to establish levels of biomarker associated with efficacy and assisting in defining biologically effective dose range selection for first dose in man. To follow the concentration in the tumour compartment enables to link kinetics and dynamics. in order to obtain a reliable model of tumour growth dynamics and drug effects, specific aspects of the modelling of the concentration-effect relationship in cancer treatment that need to be accounted for include: the physiological/circadian rhythms of the cell cycle; the treatment with combinations and the need to optimally choose appropriate combinations of the multiple agents to study; and the schedule dependence of the response in the clinical situation.
|
|
